Drugs Containing Excipient (Inactive Ingredient) SACCHARIN SODIUM MONOHYDRATE

« Back to Dashboard

Branded drugs containing SACCHARIN SODIUM MONOHYDRATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals LLC	ALBENZA	albendazole	64896-693	SACCHARIN SODIUM MONOHYDRATE
Central Texas Community Health Centers	ALBENZA	albendazole	76413-145	SACCHARIN SODIUM MONOHYDRATE

Generic drugs containing SACCHARIN SODIUM MONOHYDRATE excipient

Company	Ingredient	NDC	Excipient
ATLANTIC BIOLOGICALS CORP	dicyclomine hydrochloride	17856-2261	SACCHARIN SODIUM MONOHYDRATE
Amneal Pharmaceuticals LLC	albendazole	64896-693	SACCHARIN SODIUM MONOHYDRATE
Redpharm Drug	sulfamethoxazole and trimethoprim	67296-1916	SACCHARIN SODIUM MONOHYDRATE
Preferred Pharmaceuticals Inc	sulfamethoxazole and trimethoprim	68788-8607	SACCHARIN SODIUM MONOHYDRATE
ANI Pharmaceuticals Inc	fosfomycin tromethamine	70954-040	SACCHARIN SODIUM MONOHYDRATE

Saccharin Sodium Monohydrate Market Dynamics and Financial Trajectory

Last updated: August 25, 2026

Saccharin sodium monohydrate is a low-cost, high-intensity sweetener used in pharmaceutical formulations, oral-care products, foods and beverages. Its financial outlook is stable rather than high-growth. The product is a mature commodity excipient with limited standalone revenue disclosure, low switching costs for qualified buyers and price exposure to manufacturing capacity, energy, packaging and regulatory compliance.

Public company filings and commercial market reports generally combine saccharin sodium with broader artificial sweetener, pharmaceutical excipient or specialty chemical categories. A reliable standalone global market size, manufacturer revenue split or product-specific CAGR cannot be established from public sources. The strongest investable conclusions concern demand stability, supply concentration, formulation qualification barriers and margin sensitivity.

What is saccharin sodium monohydrate?

Saccharin sodium monohydrate is the hydrated sodium salt of saccharin. Its principal identifiers are:

Attribute	Data
Chemical name	Sodium 1,2-benzisothiazol-3(2H)-one 1,1-dioxide monohydrate
CAS number	6155-57-3
Related anhydrous CAS number	128-44-9
Molecular formula	C7H4NNaO3S·H2O
Molecular weight	Approximately 223.18 g/mol
Sweetness intensity	Commonly reported at roughly 200 to 700 times sucrose, depending on comparison method
Principal functions	Sweetening agent, taste masker and flavor modifier
Typical dosage form exposure	Oral tablets, chewable tablets, oral liquids, lozenges, dental products and some nutraceutical formulations

The monohydrate and anhydrous forms are chemically related but are not automatically interchangeable in a finished formulation. Water content affects assay calculations, material balance, density and, in some products, dissolution and stability. A formulation change normally requires supplier qualification, analytical comparability and regulatory assessment.

Saccharin is evaluated internationally as food additive E954. The Joint FAO/WHO Expert Committee on Food Additives has established an acceptable daily intake for saccharin and its salts of 0 to 5 mg/kg body weight, expressed as saccharin equivalents [1]. The European Food Safety Authority applies the same group ADI of 5 mg/kg body weight per day [2].

How large is the saccharin sodium monohydrate market?

No authoritative public source reports a standalone global market value for saccharin sodium monohydrate as a pharmaceutical excipient. Market estimates that combine saccharin, sodium saccharin, artificial sweeteners or pharmaceutical excipients should not be treated as direct measures of this product.

The addressable market has four overlapping segments:

Segment	Demand characteristics	Financial relevance
Pharmaceutical excipient	Small volume relative to food use, but higher qualification requirements	Supports recurring demand and modest quality premiums
Food and beverage	Larger volume base and price-sensitive purchasing	Drives manufacturing scale and global capacity
Oral care	Uses saccharin sodium for sweetness and taste correction	Provides stable demand from toothpaste and mouthwash producers
Nutraceuticals and consumer health	Used in tablets, powders and liquids	Growth tied to supplements, OTC products and reformulation

Pharmaceutical use is unlikely to represent the majority of global saccharin sodium demand. Food, beverage and oral-care applications provide the volume base. Pharmaceutical demand contributes better documentation, traceability and potentially higher realized prices, but it does not create the same volume leverage as food-grade production.

A reasonable commercial interpretation is that saccharin sodium monohydrate is a mature, low-value-per-kilogram ingredient with stable underlying demand and limited pricing power for producers. Market growth is more likely to track low-single-digit volume expansion, regional healthcare production and consumer-health activity than to reflect a specialty-pharmaceutical growth curve.

What drives demand for saccharin sodium monohydrate?

Demand is supported by several formulation and manufacturing characteristics.

High sweetness at low use levels

Saccharin sodium produces strong sweetness at very low concentrations. This reduces the mass of excipient required per unit and limits its cost contribution to most finished pharmaceutical products.

Taste masking

The material is used in oral dosage forms where the active ingredient has a bitter or metallic taste. It can be combined with flavors, polyols and other sweeteners to improve patient acceptance.

Water solubility

The sodium salt is more suitable than saccharin acid for aqueous and partially aqueous formulations. This supports use in oral liquids, mouthwashes and certain reconstituted products.

Thermal and processing utility

Saccharin sodium can tolerate common pharmaceutical and consumer-product processing conditions. Its suitability still depends on pH, excipient compatibility, packaging and the presence of reactive active ingredients.

Established regulatory history

Saccharin and its salts have long regulatory histories in food and consumer products. That history reduces adoption friction for conventional uses, although each drug product still requires excipient qualification and product-specific regulatory review.

How does pharmaceutical demand compare with food and beverage demand?

Food and beverage demand is larger, while pharmaceutical demand is more specification-intensive.

Factor	Pharmaceutical use	Food and beverage use
Purchase volume	Lower	Higher
Quality documentation	High	Variable by grade and jurisdiction
Price sensitivity	Moderate	High
Supplier switching	Slow because of qualification	Faster for standard grades
Regulatory file requirements	Strong identity, purity and impurity controls	Food additive compliance
Margin potential	Higher for compendial and documented grades	Lower for bulk commodity grades
Demand volatility	Linked to drug production and product launches	Linked to consumer demand and sweetener substitution

A pharmaceutical buyer may pay a premium for a compendial grade, validated analytical methods, change-control procedures, audit support and reliable batch documentation. That premium is limited by the availability of alternative suppliers and the small quantity used in most formulations.

Which regulations govern saccharin sodium monohydrate?

Regulatory treatment depends on intended use and jurisdiction.

United States

The U.S. Food and Drug Administration regulates sodium saccharin as a food additive under 21 C.F.R. §180.37 [3]. Drug manufacturers use the FDA Inactive Ingredient Database to assess precedent for excipient use in approved drug products [4]. Presence in the database does not constitute a universal approval for all dosage forms, strengths or routes of administration.

A pharmaceutical supplier generally needs to support:

• Identity and assay testing
• Water content or loss-on-drying control
• Related substances and impurity testing
• Residual solvent controls
• Elemental impurity assessment
• Microbiological quality where applicable
• Stability and retest-period data
• Manufacturing-site and change-control documentation

European Union

Saccharin is authorized as food additive E954 under the European Union food additive framework. Pharmaceutical use is assessed through the finished medicinal product dossier and applicable European Pharmacopoeia or supplier specifications. The European Medicines Agency maintains excipient-related guidance, but product approval remains formulation-specific [5].

International markets

China, India, Japan and other major pharmaceutical markets apply local pharmacopoeial, food additive and drug-registration requirements. The same manufacturer may sell separate grades for food, pharmaceutical and technical applications. Regulatory documentation and audit readiness are important commercial differentiators in regulated markets.

What patents protect saccharin sodium monohydrate?

No commercially important composition-of-matter patent is expected to protect saccharin sodium monohydrate as a mature chemical entity. Saccharin was discovered and commercialized more than a century ago, placing the core compound far beyond ordinary patent protection.

The relevant intellectual-property categories are:

1. Manufacturing processes, including reaction conditions, purification and crystallization.
2. Particle-size control and morphology.
3. Formulation combinations involving saccharin sodium with active pharmaceutical ingredients.
4. Taste-masking systems and oral-delivery technologies.
5. Packaging, impurity-control or continuous-processing methods.

These rights generally protect a particular process or finished formulation rather than the commodity excipient itself. Patent value is therefore product-specific. A generic drug manufacturer is unlikely to face a standalone patent barrier merely because it purchases or uses saccharin sodium monohydrate, but it may face method-of-use, formulation or manufacturing patents covering the finished drug.

Publicly reported patent litigation focused specifically on commercial saccharin sodium monohydrate supply is limited. The absence of visible litigation does not mean that every supplier process is unpatented. It indicates that the principal competitive barriers are more likely to be quality systems, capacity, customer qualification and regulatory documentation than enforceable composition patents.

How strong is the supplier and manufacturing barrier?

The manufacturing barrier is moderate for pharmaceutical-grade material and low to moderate for standard food-grade material.

The chemical process is mature, and multiple producers operate across Asia and other manufacturing regions. The commercial barrier increases when a buyer requires:

• United States Pharmacopeia or European Pharmacopoeia compliance
• Dedicated pharmaceutical production controls
• Full traceability to starting materials
• Audit access
• Validated cleaning and cross-contamination controls
• Tight limits for specified impurities
• Long-term supply commitments
• Formal notification of manufacturing changes

The key operational risk is not the inability to synthesize saccharin sodium. It is the ability to produce consistent batches, maintain documentation and avoid regulatory disruption.

Supply-chain exposure includes:

• Regional concentration of chemical production
• Dependence on imported starting materials
• Energy and utility costs
• Freight and container availability
• Currency movements
• Environmental controls for sulfur- and nitrogen-containing process streams
• Local export restrictions or customs delays

Because the ingredient is inexpensive and usually used at low dosage, freight cost can materially affect delivered economics in smaller orders. Buyers often manage this risk through dual sourcing, annual qualification and safety stock.

What is the financial trajectory for saccharin sodium monohydrate?

The financial trajectory is best characterized as stable revenue with periodic price volatility, rather than structural high growth.

Revenue outlook

Revenue should remain supported by:

• Continued use in oral pharmaceutical products
• Demand for low-calorie sweeteners
• Oral-care consumption
• Growth in nutraceutical and OTC products
• Recurring purchasing by established drug manufacturers

Growth is constrained by:

• Low unit consumption per finished product
• Substitution by sucralose, aspartame, acesulfame potassium, steviol glycosides and newer sweeteners
• Consumer preference shifts toward “natural” ingredients
• Limited pharmaceutical innovation requiring saccharin specifically
• Mature use in many legacy formulations

Margin outlook

Producer margins are sensitive to manufacturing utilization and input costs. During periods of excess capacity, standard-grade prices can compress quickly because the product is relatively standardized. Pharmaceutical-grade documentation can support a premium, but the premium is limited by buyer qualification of alternative suppliers.

The highest-value commercial position is not bulk saccharin sodium. It is a documented pharmaceutical grade sold with regulatory support, controlled specifications and reliable supply. Contract manufacturing, private-label excipient distribution and bundled regulatory services can improve economics more than the chemical itself.

Financial sensitivity matrix

Variable	Impact on suppliers	Impact on pharmaceutical buyers
Excess production capacity	Lower prices and weaker margins	Favorable procurement economics
Energy-cost inflation	Higher conversion costs	Potential price increases
Freight disruption	Higher delivered cost	Inventory and continuity risk
Regulatory inspection failure	Loss of customers or market access	Requalification and supply interruption
Natural-sweetener substitution	Long-term volume pressure	More formulation alternatives
Dual sourcing	Lower supplier lock-in	Higher qualification cost but lower continuity risk
Compendial grade demand	Higher documentation cost and price premium	Better compliance and lower regulatory risk

When does saccharin sodium monohydrate lose exclusivity?

Saccharin sodium monohydrate has no meaningful remaining compound exclusivity period. The compound is generic and available from multiple suppliers.

There is no conventional Hatch-Waxman exclusivity timeline for the excipient itself. Exclusivity may still arise indirectly from:

• A patented finished-drug formulation
• A patented taste-masking system
• A drug-specific method of use
• A supplier’s proprietary manufacturing process
• A confidential customer specification

Those rights attach to the formulation, process or finished product, not to ordinary ownership of saccharin sodium monohydrate.

What generic entry risks exist?

Generic entry risk is indirect and product-specific.

For a finished drug that uses saccharin sodium monohydrate, a generic applicant must address the reference product’s formulation, inactive-ingredient suitability and applicable patent or regulatory requirements. The excipient itself normally does not prevent generic entry.

The principal risks for originators are:

• Generic substitution using another sweetener
• Formulation replication with a different grade or supplier
• Paragraph IV challenges to patents covering the finished product
• Formulation patents claiming ratios, particle sizes or taste-masking systems
• Method-of-use patents unrelated to the excipient’s basic chemical identity

The principal risks for excipient suppliers are customer concentration, quality deviations, manufacturing changes and loss of pharmaceutical qualification.

What competitive products threaten saccharin sodium monohydrate?

Alternative	Competitive advantage	Limitation
Sucralose	Strong sweetness and broad formulation use	Higher cost and different regulatory profile
Aspartame	Familiar flavor profile in blends	Stability and phenylalanine labeling considerations
Acesulfame potassium	Good heat stability and blending utility	Different taste profile
Steviol glycosides	Natural-origin positioning	Bitterness and formulation variability
Sugar alcohols	Bulk, mouthfeel and low-calorie positioning	Larger required quantities and gastrointestinal limits
Neotame or advantame	Very high sweetness	Lower volume and narrower market familiarity

Substitution is more likely in new product development than in mature approved medicines. Once a drug formulation is commercialized, the cost of changing an excipient, conducting stability work and obtaining regulatory approval can exceed the ingredient savings.

What is the outlook for investors and pharmaceutical buyers?

For investors, saccharin sodium monohydrate is unlikely to be a standalone high-growth thesis. Its value is more relevant as part of a diversified excipient, sweetener or specialty-chemical portfolio. Attractive positions may come from suppliers that combine:

• Pharmaceutical-grade production
• Broad regulatory coverage
• Multiple geographic manufacturing sites
• Strong customer qualification records
• Integrated distribution
• Higher-value excipient products

For pharmaceutical buyers, the commercial priorities are supply continuity and documentation rather than price alone. A low-cost excipient can create disproportionate financial exposure if a supplier failure delays batch release or requires formulation requalification.

Key Takeaways

• Saccharin sodium monohydrate is a mature, generic excipient and high-intensity sweetener.
• Public sources do not provide a defensible standalone global market size or product-specific CAGR.
• Food, beverage and oral-care applications drive volume; pharmaceutical applications support higher documentation premiums.
• The compound has no meaningful remaining composition-of-matter exclusivity.
• Commercial barriers center on quality systems, compendial compliance, manufacturing consistency and customer qualification.
• Revenue is likely to be stable with periodic input-cost and capacity-driven price volatility.
• Long-term substitution risk comes from sucralose, acesulfame potassium, steviol glycosides and other sweeteners.
• Finished-drug patent risk may apply to formulations or methods of use, but ordinary use of the excipient is not generally patent-blocked.
• Supplier selection should prioritize dual sourcing, change control, auditability and regulatory support.

FAQs about saccharin sodium monohydrate

Is saccharin sodium monohydrate the same as sodium saccharin?

They are closely related but not identical physical forms. Saccharin sodium monohydrate contains one molecule of crystallization water, while anhydrous sodium saccharin does not. The distinction affects molecular weight, assay calculations and formulation material balance.

Is saccharin sodium monohydrate suitable for oral liquids?

Yes, sodium saccharin is used in oral liquids and other aqueous or partially aqueous products because the sodium salt has useful water solubility. Suitability depends on pH, active-ingredient compatibility, preservative system and finished-product stability.

Does saccharin sodium monohydrate require a pharmaceutical-grade certificate?

The requirement depends on the product, market and quality agreement. A regulated medicinal product generally requires documented specifications and supplier controls suitable for the finished-product dossier. A food-grade certificate is not automatically equivalent to pharmaceutical-grade qualification.

Can a drug company replace saccharin sodium monohydrate with sucralose?

Not without formulation assessment. The replacement can change sweetness intensity, taste profile, impurity control, osmolality, stability and regulatory documentation. A marketed drug may require comparability work and regulatory notification or approval.

Is saccharin sodium monohydrate exposed to biosimilar competition?

No direct biosimilar competition applies to the excipient. Biosimilar products may use saccharin sodium or another sweetener in their formulations, but the commercial risk arises from competition between finished biologic products, not from biosimilar exclusivity over the excipient.

References

1. Joint FAO/WHO Expert Committee on Food Additives. (1993). Evaluation of certain food additives and contaminants: Forty-first report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organization.

2. European Food Safety Authority. (2011). Scientific opinion on the re-evaluation of saccharin and its sodium, potassium and calcium salts as food additives. EFSA Journal, 9(10), 2316.

3. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 180.37: Sodium saccharin. Electronic Code of Federal Regulations.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.

5. European Medicines Agency. (2018). Guideline on the quality of water for pharmaceutical use. EMA.